Close Menu

NEW YORK – Cellino Biotech on Monday announced that it has raised $16 million in a seed financing round, which it will put toward advancing its artificial intelligence-based platform for autologous cell- and tissue-based therapies.

Cambridge, Massachusetts-based Cellino's seed financing was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC. "This seed financing round enables us to build towards a democratized future for autologous cells and tissues," Cellino CEO and Cofounder Nabiha Saklayen said in a statement.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.